Last reviewed · How we verify
Prevention of clot formation during haemodialysis
Approved treatments
- Lovenox (Preservative Free) · Sanofi
Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting. - Lovenox · University of Monastir
- Enoxaparin · Dana-Farber Cancer Institute
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of clot formation during haemodialysis patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of clot formation during haemodialysis treatment landscape brief
- Prevention of clot formation during haemodialysis treatment updates RSS
Frequently asked questions about Prevention of clot formation during haemodialysis
What drugs treat Prevention of clot formation during haemodialysis?
Tracked treatments include Lovenox (Preservative Free), Lovenox, Enoxaparin.
What is the treatment for Prevention of clot formation during haemodialysis?
Standard treatment for Prevention of clot formation during haemodialysis includes Lovenox (Preservative Free), Lovenox, Enoxaparin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of clot formation during haemodialysis patent cliff · Prevention of clot formation during haemodialysis CI report
- Treatment: Lovenox (Preservative Free) · Sanofi
- Treatment: Lovenox · University of Monastir
- Treatment: Enoxaparin · Dana-Farber Cancer Institute
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing